Cantor reiterated $CAPR Overweight-$30 and said "Management addressed the recent headlines floating around after recent staffing changes at the FDA."
$EWTX $SRPT
Cantor added, "They don't believe that Dr. Verdun was placed on administrative leave related specifically to $CAPR's review.
They suggested that the FDA would be unlikely to take a step this drastic as Dr. Prasad could easily just overrule a decision.
As of last Friday afternoon, the company was notified that the Agency does not see the need for an advisory committee meeting at this time."
/filters:format(webp)/production/1703581/large-1557087590.png)
Oppenheimer reiterated $CAPR at Outperform-$43 and said it has increased confidence heading into deramiocel's potential approval for DMD cardiomyopathy.
$EWTX $SRPT
H.C. Wainwright reiterated $CAPR Buy-$77 and noted $CAPR expressed confidence that its facility is well-positioned to meet FDA requirements - barring future unforeseen issues, HCW believes any current concerns regarding manufacturing are unwarranted.
Oppenheimer said in its note to investors:
/filters:format(webp)/images/default_avatar_11_large.png){kind=avatar}